WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · LC 3271

LC 3271 Summary — Generally revise laws related to prior authorization for psychiatric medications related to schizophrenia

Quick snapshot

  • Bill Number: LC 3271
  • Title: Generally revise laws related to prior authorization for psychiatric medications related to schizophrenia
  • Status: Draft Died in Process (LC)
  • Introduced: December 14, 2024
  • Classification/Subject: Health; Health Care Services; Safety; Insurance

Purpose and intent

Based on the title, LC 3271 seeks to revise the laws governing prior authorization (PA) for psychiatric medications used to treat schizophrenia. The bill appears designed to reform how insurers or drug benefit programs review, approve, or deny claims for these medications, with the goals typically associated with PA reform—reducing unnecessary delays, increasing transparency, and protecting patient access to clinically appropriate treatments.

Key provisions (not specified in the text provided)

The exact provisions are not included in the information given. If enacted, bills of this type commonly address elements such as:
- Timeframes for processing PA requests (standardized review timelines, including urgent/emergency review paths)
- Criteria and documentation required for PA determinations
- Procedures for expedited or automatic approvals in certain clinical circumstances
- Requirements for insurers to notify prescribers and patients with clear rationale for approvals or denials
- Appeals and denial reconsideration processes with defined timelines
- Prohibitions or safeguards against retroactive denials and unnecessary reliance on formulary restrictions
- Reporting and oversight requirements to monitor PA decisions and patient outcomes
- Consumer protections and patient-access provisions specific to schizophrenia treatment plans

Note: The above items reflect common components of PA reform bills and are not stated assurances for LC 3271 without the full text.

Affected parties

  • Patients with schizophrenia and their families, who rely on timely access to appropriate psychiatric medications.
  • Prescribers and mental health professionals who manage treatment plans and PA submissions.
  • Insurers, health plans, and pharmacy benefit managers implementing PA processes.
  • Advocacy groups focusing on access to mental health care and patient protections.

Procedural and timeline aspects

  • Introduced: December 14, 2024
  • Drafter Assigned: December 14, 2024
  • Status update: Draft Died in Process as of May 27, 2025, indicating the measure did not advance beyond the drafting stage in this session.

Potential impact

  • If enacted, the bill could streamline or standardize PA for schizophrenia medications, potentially reducing treatment delays and improving transparency.
  • Could alter insurer administrative practices, affecting workflow for clinicians and patients.
  • With a “Died in Process” fate, the proposal currently has no enacted impact; it may be reintroduced in a future session or in a revised form.

Next steps

  • Monitor for any reintroduction or amendments in subsequent legislative sessions.
  • If text becomes available, review for specific provisions, timelines, and the exact scope of changes to PA processes.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.